Thymocyte Drug Target of Immune Reconstitution

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$270,181.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI060447-01
Agency Tracking Number:
AI060447
Solicitation Year:
2004
Solicitation Topic Code:
N/A
Solicitation Number:
PHS2004-2
Small Business Information
ORPHAGEN PHARMACEUTICALS
ORPHAGEN PHARMACEUTICALS, 5310 EASTGATE MALL, SAN DIEGO, CA, 92121
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
N/A
Principal Investigator
 SCOTT Thacher
 (858) 625-0540
 smt@orphagen.com
Business Contact
 TIM SCOTT
Phone: (858) 625-0540
Email: TSCOTT@ORPHANGEN.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): The long-term objective of this proposal is to develop the first class of small molecule, orally-bioavailable drugs that increases T cell production from the thymus and enhances immune reconstitution in AIDS and other

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government